chemical:semaglutide
Kidney injuries on Ozempic
Recent reports of kidney injuries have caused a change in requirements for GLP1 labeling. We dive into the actual risk and what you can do about it.
GLP1.Guide Staff
Scouring sources for information on GLP1 Agonist drugs, so you don't have to.
drug:mounjaro
Mounjaro vs Trulicity in a clinical trial
Trulicity and Mounjaro go head to head, in a clinical trial that finally puts to bed the question of which is better.
politics
Medicare/Medicaid might pay for GLP1s again
GLP1s might be covered under Medicare/medicaid again. The Trump administration introduces a new experiment under the CMMI.
drug:phentermine
Boosting GLP1s with Phentermine
Reports of combining GLP1s with Phentermine suggest superior results. What is Phentermine and how can it be used with GLP1s?
chemical:semaglutide
Another GLP1 Generic launch: India's Dr Reddy's
Yet another manufacturer signs up to produce generic Semaglutide for much of the world (ex. EU and USA) - what does Dr. Reddy's have planned?
company:hims
Hims will sell generic Semaglutide in 2026
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
company:novo-nordisk
Novo Nordisk is introducing a higher dose of Wegovy
Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
company:weight-watchers
Novo's expanding collaboration with Weight Watchers
Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
drug:wegovy
Less for Less: CVS drops Zepbound for Wegovy
CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
includes:study
If GLP1 is so great, why don't people stick with it?
Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.
category:news
A glowing endorsement of GLP1s by cardiologists
Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
category:risks
A new risk? Macular Degeneration
We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.